מזומני החברה: Generation Bio Corp (GBIO)

Generation Bio Co. (GBIO) is implementing an innovative non-viral delivery system for large DNA fragments, enabling the repeated administration of drugs. The project is currently in its early stages without stable revenue, relying instead on the search for strategic partners. The potential of this unique platform will ensure future pricing power. This cash balance chart demonstrates current liquidity, where 0.09 is recorded as the baseline value.
פילוחים אנליטיים ודוחות נתונים של חברת Generation Bio Co. (GBIO)

This indicator captures the net volume of liquid assets on the balance sheet, measuring the organization's ability to fund operating activities without raising external capital. Amid sanctions restrictions on biotechnology exports and the disruption of supply chains, the cash level becomes a critical reserve for sustaining Generation Bio Co. (GBIO) drug development when global research is hindered by geopolitical isolation.